1. Scrip
  2. >>Business
  3. >>Strategy

Moderna Reports ‘Robust’ Response From COVID-19 Booster Shots

Pipeline Sees Continued Progress, Helped By Vaccine Windfall

 
• By Alaric DeArment

Executives said the company was “capacity constrained” for 2021 and not taking further mRNA-1273 vaccine orders for delivery this year.

Moderna vaccine
Moderna's COVID-19 vaccine provided the company with a huge windfall as it registered a $2.3bn profit • Source: Shutterstock

With proof of concept in the form of its wildly successful vaccine against SARS-CoV-2 infection, Moderna, Inc.is now taking its messenger RNA show on the R&D road as it reports progress in its platform in infectious diseases apart from COVID-19 and beyond infectious diseases as well. However, the pandemic still looms large for the company, which also released data showing that booster shots of its vaccine produced strong immune responses against the coronavirus.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By Kevin Grogan

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.